We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

Perioperative Pembrolizumab or Pembrolizumab plus Enfortumab Vedotin (EV) and Cystectomy Compared to Cystectomy Alone in Patients With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible (KEYNOTE-905/EV-303)

Submitted

19 Views
0 Downloads
0 Saves
Presented at
Global Congress on Bladder Cancer 2020

-

Presentation

thumbnail

Abstract

Datasets

No datasets are available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2021 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2021 Morressier GmbH.
All rights reserved.